OBJECTIVES: Data on therapeutic endoscopic retrograde cholangiopancreatography (ERCP) for chronic pancreatitis (CP) in children and adolescents, especially with long-term follow-up of consequences, are rarely reported. The aim of this study was to determine the long-term follow-up results of therapeutic ERCP for CP in children and adolescents. METHODS: All patients with CP who received therapeutic ERCP at Changhai Hospital from January 1997 to May 2009, with the age at first onset of pain being less than 18.0 years, were included. Attempts were made to contact all adolescents and follow-up data were recorded. Clinical data were assessed before and after every ERCP. RESULTS: Follow-up information was available in 42 (91.3%) of the 46 patients who received therapeutic ERCP. There were 20 boys and 22 girls, with the age at first onset being 11.8+/-4.5 years. A total of 110 therapeutic ERCP sessions were performed in the 42 patients. The post-ERCP complication rate was 17.3%, including mild and moderate pancreatitis (n=17) and mild cholangitis (n=2). The mean follow-up period of time was 61.4 (range: 24-132) months. Five patients underwent subsequent surgery because of refractory abdominal pain after endotherapy. Of the remaining 37 patients who received therapeutic ERCP alone, abdominal pain improved in 30 (81.1%) patients, and was completely relieved in 24 (64.9%) patients during the period of follow-up. CONCLUSIONS: Therapeutic ERCP may offer long-term improvement in pain in children and adolescents with CP.
OBJECTIVES: Data on therapeutic endoscopic retrograde cholangiopancreatography (ERCP) for chronic pancreatitis (CP) in children and adolescents, especially with long-term follow-up of consequences, are rarely reported. The aim of this study was to determine the long-term follow-up results of therapeutic ERCP for CP in children and adolescents. METHODS: All patients with CP who received therapeutic ERCP at Changhai Hospital from January 1997 to May 2009, with the age at first onset of pain being less than 18.0 years, were included. Attempts were made to contact all adolescents and follow-up data were recorded. Clinical data were assessed before and after every ERCP. RESULTS: Follow-up information was available in 42 (91.3%) of the 46 patients who received therapeutic ERCP. There were 20 boys and 22 girls, with the age at first onset being 11.8+/-4.5 years. A total of 110 therapeutic ERCP sessions were performed in the 42 patients. The post-ERCP complication rate was 17.3%, including mild and moderate pancreatitis (n=17) and mild cholangitis (n=2). The mean follow-up period of time was 61.4 (range: 24-132) months. Five patients underwent subsequent surgery because of refractory abdominal pain after endotherapy. Of the remaining 37 patients who received therapeutic ERCP alone, abdominal pain improved in 30 (81.1%) patients, and was completely relieved in 24 (64.9%) patients during the period of follow-up. CONCLUSIONS: Therapeutic ERCP may offer long-term improvement in pain in children and adolescents with CP.
Authors: D Kohoutova; A Tringali; G Papparella; V Perri; I Boškoski; J Hamanaka; G Costamagna Journal: United European Gastroenterol J Date: 2018-12-05 Impact factor: 4.623
Authors: David M Troendle; Douglas S Fishman; Bradley A Barth; Matthew J Giefer; Tom K Lin; Quin Y Liu; Maisam Abu-El-Haija; Melena D Bellin; Peter R Durie; Steven D Freedman; Cheryl Gariepy; Tanja Gonska; Melvin B Heyman; Ryan Himes; Sohail Z Husain; Soma Kumar; Mark E Lowe; Veronique D Morinville; Chee Y Ooi; Joseph Palermo; John F Pohl; Sarah Jane Schwarzenberg; Steven Werlin; Michael Wilschanski; M Bridget Zimmerman; Aliye Uc Journal: Pancreas Date: 2017-07 Impact factor: 3.327
Authors: Emily R Perito; John F Pohl; Caitlin Bakker; Matthew A Armfield; Bradley Barth; Addison Cuneo; Maria Mascarenhas; Megha Mehta; Sarah Jane Schwarzenberg Journal: Pancreas Date: 2022-02-01 Impact factor: 3.327
Authors: F Khanim; N Davies; P Veliça; R Hayden; J Ride; C Pararasa; M G Chong; U Gunther; N Veerapen; P Winn; R Farmer; E Trivier; L Rigoreau; M Drayson; C Bunce Journal: Br J Cancer Date: 2014-02-25 Impact factor: 7.640